Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. Headquartered in San Diego, California, and co-founded by Catalys Pacific and Novo Holdings, Crystalys brings together a world-class team with deep expertise in gout drug development, dedicated to delivering more effective options for people living with gout. The company's lead candidate, dotinurad, is a next-generation, once daily oral, URAT1 inhibitor in clinical development as a second-line therapy aimed to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has obtained regulatory approval in Japan, China, Philippines and Thailand. With best-in-class potential for both safety and efficacy, dotinurad is supported by clinical data from multiple Asian markets where it is approved. Crystalys is advancing dotinurad in global Phase 3 trials toward regulatory approval and commercial launch.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
10/06/25	$205,000,000	Series A	Aberdeen Investments Alexandria Venture Investments AN Ventures Catalys Pacific KB Investments Lightstone Ventures Longwood Fund Novo Holdings Perceptive Xontogeny Venture Fund Pontifax Prebys Ventures Fund SR One Wedbush Healthcare Partners	undisclosed